Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant
Por um escritor misterioso
Descrição
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.
Management of Castration-Resistant Prostate Cancer
A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer
Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
ASCO GU 2019: Initial Results from a Phase II Study of Nivolumab plus Ipilimumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer - CheckMate 650
Cancers, Free Full-Text
Ipilimumab - Wikipedia
Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-Resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial - Beyond the Abstract
FDA Approves Nivolumab Plus Ipilimumab for the Treatment of Advanced HCC
Frontiers Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy
de
por adulto (o preço varia de acordo com o tamanho do grupo)
